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This phase II trial was performed to evaluate the efficacy and tolerability of oral tegafur–uracil (UFT
s) with leucovorin (LV)
combined with intravenous (i.v.) irinotecan every 3 weeks (TEGAFIRI) as first-line treatment for patients with metastatic colorectal
cancer (mCRC). Patients received oral UFT 250mgm
 2day
 1 and LV 90mgday
 1 in three divided daily doses for 14 days followed
by a 1-week rest and i.v. irinotecan 250mgm
 2 as a 90-min infusion every 3 weeks. Tumour responses, assessed every two cycles
using RECIST criteria, were reviewed by an independent review committee. In 52 evaluable patients, the best overall response rate
was 33% (95% confidence intervals (CI) 20–47%; 1 complete and 16 partial responses). The median time to progression was 5.4
months (95% CI 3.02–7.52 months) and median overall survival was 14.9 months (11.73–17.97 months). A total of 307 cycles were
administered, with a median number of five cycles per patient (range: 1–10). The most common grade 3/4 toxicities were
neutropenia (25% of patients), diarrhoea (22%), vomiting (11%) and anaemia (11%). The TEGAFIRI regimen is a feasible, well-
tolerated and convenient treatment option for patients with non-resectable mCRC.
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The use of fluoropyrimidine therapy for patients with colorectal
cancer (CRC) is now well established. 5-Fluorouracil (5-FU)-based
chemotherapy has been the mainstay of treatment for advanced
and metastatic colorectal cancer (mCRC) since its introduction in
1957. In recent years, enormous efforts have gone into improving
its efficacy, including biochemical modulation and changing the
method of its administration. The biomodulation of 5-FU by
leucovorin (LV) has been shown to significantly improve response
rates and prolong survival with high- and low-dose LV schedules
(Bobbio-Pallavicini et al, 1993; Petrioli et al, 1995; Borner et al,
1998). Administration of 5-FU via continuous infusion has resulted
in significantly better response rates when compared with bolus
intravenous (i.v.) 5-FU, as demonstrated in a meta-analysis of six
randomised studies (Meta-Analysis Group in Cancer, 1998),
although only a modest survival benefit (12.1 vs 11.3 months;
Po0.04) was demonstrated. The continuous infusion regimen was
associated with a greater incidence of hand–foot syndrome (34 vs
13%), but the incidence of grade 3/4 neutropenia was significantly
reduced.
In an attempt to improve the therapeutic index of 5-FU, research
has also focussed on the study of 5-FU prodrugs and the selection
of drugs with a better bioavailability profile, the aim being to
increase tumour exposure and to reduce the complexity involved
with continuous i.v. infusion administration. UFT is a combination
of tegafur, an oral precursor of 5-FU, and uracil, a reversible
dihydropyrimidine dehydrogenase (DPD) inhibitor. Tegafur is
converted into 5-FU by the hepatic cytochrome P450 pathway (El
Sayed and Sadee, 1982), whereas uracil enhances the half-life of
converted 5-FU by competing for its degradation by DPD, this
being the rate-limiting enzyme in the catabolism of 5-FU. Current
clinical experience indicates that UFT with LV is a convenient,
well-tolerated and effective alternative to i.v. 5-FU/LV for the
treatment of advanced CRC. Two large, randomised phase III
studies compared UFT plus LV given for 28 days every 35 days vs
parenteral 5-FU/LV administered for 5 days every 28 or 35 days in
previously untreated patients with mCRC (Carmichael et al, 2002;
Douillard et al, 2002). In both studies, the oral and i.v. regimens
resulted in comparable response rates and overall survival.
However, substantial safety benefits were observed in the UFT
plus LV group, with patients experiencing significantly less
stomatitis/mucositis and myelosuppression, resulting in fewer
episodes of febrile neutropenia.
In recent years, the introduction of chemotherapeutic agents,
such as irinotecan, oxaliplatin and capecitabine, has led to
significant advances in the treatment of patients with mCRC.
The topoisomerase I inhibitor irinotecan was initially introduced
as monotherapy for patients with mCRC refractory to 5-FU. In two
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srandomised phase III trials, second-line irinotecan extended
survival significantly when compared with supportive care
(Cunningham et al, 1998) or 5-FU/LV infusion as second-line
therapy (Rougier et al, 1998). In the first-line setting, the
irinotecan plus 5-FU/LV combination produced better tumour
response rates and longer progression-free and overall survival
times than 5-FU/LV alone (bolus or infusion 5-FU regimens) in
two large randomised clinical trials (Douillard et al, 2000; Saltz
et al, 2000).
The convenient route of administration of UFT with LV
combined with its efficacy and improved toxicity profile compared
with i.v. 5-FU make it an attractive option for combining with
irinotecan in the treatment of mCRC. The feasibility of this
combination was evaluated in a phase I/II study performed in
patients with advanced CRC (Price and Hill, 2000; Mackay et al,
2003). The recommended doses for further studies were UFT
250mgm
 2day
 1 and LV 90mgday
 1 given on days 1–14 with
i.v. irinotecan 250mgm
 2 administered on day 1 every 3 weeks.
The main dose-limiting toxicities were diarrhoea and febrile
neutropenia (Mackay et al, 2003). Therefore, we initiated a phase II
study using this dosage regimen to determine the efficacy and
safety of the combination as first-line treatment for patients with
mCRC.
MATERIALS AND METHODS
Patient selection
Patients with histologically or cytologically confirmed mCRC not
suitable for curative surgery were included in this study. Prior
major surgery, radiation and adjuvant or neoadjuvant chemo-
therapy had to be completed at least 4 weeks before study entry.
Further eligibility criteria included male or female patients aged
X18 years; at least one uni- or bi-dimensionally measurable lesion;
adequate bone marrow (absolute neutrophil count (ANC) X1.5 
10
9l
 1, platelets 4100 10
9l
 1), liver (bilirubin p1.5 upper
limit of normal (ULN) and transaminases p2.5 ULN or
p5 ULN in case of hepatic metastasis) and kidney (serum
creatinine p1.5 ULN) functions; Eastern Cooperative Oncology
Group performance status of 0 or 1 and life expectancy X12 weeks.
Patients were excluded if they showed evidence of central nervous
system metastases, serious intercurrent infections or concurrent
active malignancies. Prior chemotherapy for metastatic disease was
not permitted. Patients were excluded if prior radiation therapy
had included a target lesion, unless the lesion was shown to have
progressed after completion of radiation treatment or the patient
had target lesions outside of any radiation ports. All patients
provided written informed consent. The study was conducted in
accordance with the Declaration of Helsinki Principle and Good
Clinical Practice and was approved by an independent ethics
committee.
Treatment
UFT 250mgm
 2day
 1 and LV 90mgday
 1 were given together, in
three divided daily doses, for 14 days (days 1–14), followed by a
1-week rest period; irinotecan 250mgm
 2 was administered as a
90-min i.v. infusion on day 1 of the 3-week cycle. No food could to
be taken 1h before or 1h after each UFT dose. Duration of
treatment was based on tumour response: patients with stable
disease or a partial response (PR) could receive treatment until
progression; those with a complete response (CR) could continue
treatment for up to four cycles after documentation of CR.
Dosage modifications for both UFT and irinotecan were planned
in the case of severe haematological and/or non-haematological
toxicities.
During a treatment cycle, UFT/LV was withheld if a grade 4
haematological toxicity or a grade X2 non-haematological toxicity
developed (National Cancer Institute Common Toxicity Criteria
(NCI-CTC), Version 2.0, 1998). In particular, patient with grade 2
diarrhoea were supposed to stop the treatment until toxicity
resolved to baseline or grade p1.
For the subsequent cycles, a maximum of 2 weeks for initiation
of treatment was tolerated. Treatment was not resumed until
haematological recovery (ANC X1.5 10
9l
 1 and platelets
X75 10
9l
 1) and non-haematological toxicity resolved to
baseline (except any grade of alopecia). Following grade 4
haematological toxicity, febrile neutropenia or grades 2–4 non-
haematological toxicity (other than alopecia or fatigue), both the
irinotecan and UFT doses were reduced by 50mgm
 2 in
subsequent treatment cycles. Once the dose of UFT and/or
irinotecan had been reduced, subsequent re-escalation of the dose
was not permitted.
Concomitant treatment for diarrhoea consisted of loperamide as
curative treatment. Standard anti-emetic therapy and premedica-
tion before the irinotecan infusion could be prescribed as required,
at the discretion of the investigator. Haematopoietic colony-
stimulating factors, antibiotics and erythropoietin could be
administered prophylactically.
Evaluation of tumour response and toxicity
Pretreatment evaluation included a complete history and clinical
examination, haematological and biochemical profiles, electro-
cardiogram, chest X-ray and computerised tomography (CT) scan
of the abdomen and other sites of disease when appropriate.
During treatment, weekly complete blood cell count with
differential and platelet count was obtained, with serum chemistry
performed every 2 cycles. Performance status and physical
examination were assessed before each cycle. Tumour assessment
by CT scan was repeated every two cycles (6 weeks) and/or at the
end of treatment, then every 3 months during follow-up using the
same method as was used at baseline.
Response was evaluated according to Response Evaluation
Criteria in Solid Tumours (Therasse et al, 2000). Complete
response was defined as the disappearance of all clinical and
radiological evidence of target lesions; PR as a X30% decrease in
the overall sum of the diameter of the target lesion(s); and
progressive disease (PD) as a X20% increase in the overall sum of
the diameter of the target lesion(s). In case of PR or CR, a second
assessment 4 weeks later was required for confirmation of
response. All tumour measurements were reviewed by an
independent review committee of radiologists. The duration of
response was calculated from the date of the first treatment to the
first date of documented progression for patients with PR and
from the date of the occurrence of the CR to the first date of
documented progression for patients with CR. Time to progression
(TTP) was calculated as the time from the first day of treatment to
the first date of documented progression or death. Overall survival
was defined as the time from the first day of therapy (informed
consent date) to the date of death.
Toxicity, graded according to the NCI-CTC (Version 2.0, 1998),
was assessed by means of clinical and biological examinations
before each cycle (weekly within a cycle for haematological
toxicity), and at the end of treatment.
Statistical analysis
This phase II study was designed using an exact single-stage
procedure to detect a tumour response rate of at least 25% in
patients with mCRC. Based on a significance level of 5% and a
power of 90%, a minimum of 49 evaluable patients was to be
included in the study. Assuming a 10% rate of non-evaluable
patients, a total of 55 patients needed to be enrolled.
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sAnalyses were performed using SAS
s (Version 8.2; SAS
Institute, Cary, NC, USA). Efficacy analyses were performed on
both the intent-to-treat (ITT) population and the evaluable
population, which was defined as all patients who received at
least two cycles of treatment and had at least one tumour
measurement. The safety analysis was performed in all patients
who received at least one dose of study drugs. The primary end
point of the study was the objective response rate (ORR), that is,
the rate of CR plus PR. The ORR was computed with two-sided
Clopper–Pearson confidence intervals (CI). Multivariate analysis
was carried out using multiple logistic regressions to determine
significant prognostic factors (among age, organ involved,
previous adjuvant chemotherapy, performance status, lactate
dehydrogenase and alkaline phosphatase at baseline); univariate
analysis was entered into the model in single step (step method).
Adjusted odds ratios and their 95% CI at the level of significance
Po0.10 were provided.
Secondary efficacy criteria were duration of response, TTP and
survival, which was estimated using the Kaplan–Meier product
limit method, calculating 95% CI for median values (Figure 1). For
toxicity analysis, the worst grade for each patient in all cycles of
chemotherapy was used according to NCI-CTC criteria.
RESULTS
From September 2002 to October 2003, 56 patients were included
and treated in the study. Four patients were excluded from the
efficacy analysis (three patients had no tumour evaluation after
baseline and one patient had o2 treatment cycles).
Patient characteristics
Patient and disease characteristics at inclusion are summarised in
Table 1. More than half of the patients were male (54%) and the
median age was 66 years (range: 42–88 years). The median time
from initial diagnosis to study entry was 1.7 months (range: 0.2–
86.2 months). Thirty-seven patients (66%) had synchronous
metastases; 22 patients (39%) had X2 metastatic sites with liver
and/or lung as primary sites of metastases. Overall, 49 patients
(88%) had received prior treatment for cancer, all of whom had
surgery and 15 of whom (27%) had received adjuvant (n¼13) or
neoadjuvant (n¼2) chemotherapy.
Treatment exposure
Overall, 307 cycles were administered to 56 patients, with a median
number of five cycles per patient (range: 1–10 cycles). The median
duration of treatment was 17 weeks (range: 3–34 weeks). The
mean (7s.d.) dose intensities of UFT (142.2724.3mgm
 2day
 1)
and irinotecan 76.877.6mgm
 2week
 1) corresponded to 85.3
and 92.2% of the scheduled doses, respectively. Treatment was
delayed in 15% of cycles, mostly for reasons other than toxicity.
The UFT and irinotecan doses were reduced in 4 and 5% of cycles,
respectively, mainly as a result of grade 3 or 4 diarrhoea. Reasons
for treatment discontinuation were: PD (n¼23); investigator’s
decision (n¼8); patient request (n¼4); drug-related toxicity
(n¼4); symptomatic deterioration without objective evidence of
progression (n¼3); death (n¼3) and other reasons (n¼11).
Independent review committee efficacy results
In the evaluable population (n¼52), the ORR was 32.7%. (95% CI
20.0–47.0%), with one CR (1.9%) and 16 PR (30.8%). Stable
disease was observed in 52% of patients. The ORR in the ITT
population (n¼56) was 30.4% (95% CI, 19.0–44.0%; Table 2).
Median response duration was 7.7 months (95% CI 56.0–9.5
months), median TTP was 5.4 months (95% CI 3.0–7.5 months);
and median survival was 14.9 months (95% CI 11.7–18.0 months).
In the multivariate analysis, only alkaline phosphatase grade at
baseline was an independent prognostic factor of the objective
response (odd ratio¼0.389 (0.148–1.020)); the lower the grade of
alkaline phosphatase at baseline, the higher the ORR.
Safety results
As expected, myelosuppression and gastrointestinal disorders were
the most commonly observed toxicities resulting from study
treatment (Table 3). Grade 3/4 neutropenia occurred in 25% of
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Figure 1 Kaplan–Meier curve of median survival.
Table 1 Patients and disease characteristics at baseline (n¼56)
Characteristic No. of patients %
Sex
Male 30 54
Female 26 46
Median age (range, years) 66.0 (42–88)
ECOG performance status
03 2 5 7
12 3 4 1
Missing 1 2
Primary site
Colon 31 55
Rectum 17 30
Colorectal 7 13
Missing 1 2
Number of organs involved
13 4 6 1
21 6 2 9
35 9
41 2
Organ involvement
Liver only 25 45
Lung only 3 5
Liver and lung 14 25
Lymph nodes 4 7
Peritoneum 2 4
Prior therapy
Surgery 49 88
Radiotherapy 9 16
Adjuvant/neoadjuvant chemotherapy 15 27
ECOG¼Eastern Cooperative Oncology Group.
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spatients and 8% of cycles (grade 4 toxicity in 13% of patients).
Only one patient experienced febrile neutropenia, which lasted for
5 days. Grade 3/4 anaemia occurred in 11% of patients and 2% of
cycles (one patient had grade 4 toxicity). Grade 4 thrombo-
cytopenia (no grade 3 thrombocytopenia was observed) occurred
in two patients (4%) and in 1% of cycles, but was not complicated
by haemorrhage.
Grade 3/4 non-haematological toxicities related to study drugs
consisted mainly of diarrhoea (23% of patients; 5% of cycles),
vomiting (11% of patients; 3% of cycles), fatigue (7% of patients;
2% of cycles) and nausea (7% of patients; 2% of cycles) (Table 3).
Only two patients experienced a grade 4 adverse event related to
the study drugs (diarrhoea and fatigue). Few patients experienced
adverse events leading to hospitalisation: grade 4 asthenia (one
patient), grade 3 dyspnoea (one patient), grade 4 mediastinitis
(one patient), all of which were systematically related, in the
investigator’s opinion, to PD. There were no treatment-related
deaths during the study. No hand–foot syndrome greater than
grade 2 was observed.
DISCUSSION
Colorectal cancer is a common disease that is difficult to treat
effectively and safely. Chemotherapy options are relatively limited
at present and more effective, well-tolerated treatments are
urgently needed to combat the considerable mortality and
morbidity associated with the disease. Given the limitations of
available chemotherapies, the tumour response rate of 33%,
disease stabilisation rate of 52% and the favourable tolerability
profile observed in this study of UFT with LV plus irinotecan is
encouraging, worthwhile and comparable with response rates
achieved with 5-FU–irinotecan combination regimens.
Combinations of 5-FU/LV with irinotecan (FOLFIRI, AIO or IFL
regimens) or oxaliplatin (FOLFOX4 or FOLFOX6 regimens) are
considered to be standard first-line treatments for patients with
mCRC (Saltz et al, 2001; Meyerhardt and Mayer, 2005). Irinotecan
has been evaluated in combination with 5-FU/LV in two large
multicentre phase III trials using either the bolus 5-FU schedule
(Mayo Clinic regimen, n¼683) in North America (Saltz et al,
2000) or a 48-h infusion programme in Europe (n¼385)
(Douillard et al, 2000). The response rates observed in those
studies (39 and 35%, respectively) are slightly higher than that
obtained in the present study (33%); however, the median overall
survival times reported by Saltz et al (14.8 months) and Douillard
et al (17.4 months) are comparable with the 14.9 months obtained
in the present study.
The efficacy of the TEGAFIRI regimen is superior to that of UFT
with LV alone and higher than the 21% response rate reported by
Mendez et al in a phase II study of weekly irinotecan combined
with UFT plus LV in the first-line setting (Mendez et al, 2005).
Interesting, results were obtained with a regimen in which UFT
with LV plus oxaliplatin was alternated with UFT with LV plus
irinotecan in 41 patients with mCRC (Petrioli et al, 2004). In that
study, an ORR of 58.5%, median overall survival of 17.3 months
and median TTP of 8.8 months were reported. Similarly, Sheikh
et al reported promising results in a phase I study of alternating
UFT–oxaliplatin and UFT–irinotecan in the first-line treatment of
patients with mCRC (Sheikh et al, 2007). A response rate of 71%
was reported in 25 patients, with a median TTP of 8.8 months. UFT
with LV has also been evaluated in combination with oxaliplatin
(the TEGAFOX regimen) using a similar 3-weekly oxaliplatin
schedule (Bennouna et al, 2006). The TEGAFOX regimen provided
similar efficacy to that of the TEGAFIRI regimen, with an ORR of
34% in 58 patients and a median TTP and survival of 5.9 and 18.2
months, respectively.
The adverse event profile of the TEGAFIRI regimen was
acceptable and consistent with results from a phase I trial in
which grade 3/4 diarrhoea and febrile neutropenia were dose
limiting (Mackay et al, 2003). Most haematological and non-
haematological adverse events in the present study were mild or
moderate in intensity. The most frequent grade 3/4 adverse events
were neutropenia and diarrhoea, which were seen in 25 and 23% of
patients, respectively. Grade 4 toxicity was infrequent and only one
patient had febrile neutropenia. As might be expected, the addition
of irinotecan to the UFT regimen was associated with a modest
increase in adverse events vs UFT with LV. In the studies by
Douillard et al (2002) and Carmichael et al (2002), the incidence of
grade 3/4 neutropenia in UFT-treated patients (3% of patients in
both studies) was lower than that observed in the present study
(25% of patients). However, the incidences of grade 3/4 diarrhoea
appeared similar (21 and 18% in the Douillard and Carmichael
studies, respectively, vs 22% in the present study). While
comparisons between clinical studies are made with caution,
grade 3/4 neutropenia appeared to be less common with the
TEGAFIRI regimen compared with the FOLFIRI combination,
occurring in 25% of TEGAFIRI patients vs 54 and 46% of patients
treated with bolus or infusional 5-FU/LV in combination with
irinotecan, respectively (Douillard et al, 2000; Saltz et al, 2000).
Table 2 Efficacy results based on IRC assessment in the ITT population
(n¼56)
Outcome Value
Best tumour response, n (%)
Complete response 1 (2)
Partial response 16 (29)
Stable disease 27 (48)
Progressive disease 5 (9)
Not evaluable 7 (13)
Overall best response rate (95% CI) 30.4 (19.0–44.0)
Median duration of response (95% CI, months) 7.69 (5.95–9.46)
Median time to progression (95% CI, months) 5.45 (3.02–7.52)
Median survival time (95% CI, months) 14.85 (11.73–17.97)
CI¼confidence interval; IRC¼independent review committee; ITT¼intent-to-treat.
Table 3 Adverse events related to study drugs reported in at least 5% of
patients according to NCI-CTC criteria
By patient (n¼56) By cycle (n¼307)
Toxicity, n (%) All grades Grade 3/4 All grades Grade 3/4
Haematological
Leucopoenia 36 (64) 6 (11) 111 (36) 13 (4)
Neutropenia 35 (63) 14 (25) 121 (39) 26 (8)
Anaemia 37 (66) 6 (11) 124 (40) 7 (2)
Thrombocytopenia 5 (9) 2 (4) 5 (2) 2 (1)
Non-haematological
Nausea 44 (79) 4 (7) 136 (44) 7 (2)
Diarrhoea 42 (75) 13 (23) 141 (46) 15 (5)
Fatigue 33 (59) 4 (7) 86 (28) 7 (2)
Alopecia 33 (59) NA 202 (66) NA
Vomiting 30 (54) 6 (11) 94 (31) 9 (3)
Abdominal pain 19 (34) 1 (2) 40 (13) 1 (o0.5)
Anorexia 10 (18) 1 (2) 13 (4) 1 (o0.5)
Constipation 6 (11) 1 (2) 7 (2) 1 (o0.5)
Pyrexia 6 (11) 0 7 (2) 0
Headache 6 (11) 0 14 (4) 0
Asthenia 4 (7) 2 (4) 15 (5) 4 (1)
Cholinergic syndrome 4 (7) 1 (2) 5 (2) 2 (1)
Weight decreased 5 (9) 0 17 (6) 0
Paraesthesia 3 (5) 0 4 (1) 0
Vertigo 3 (5) 0 4 (1) 0
NA¼not applicable; NCI-CTC¼National Cancer Institute Common Toxicity
Criteria.
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sOnly one patient (2%) in the present study experienced febrile
neutropenia, compared with 7 and 3% of patients in the Douillard
and Saltz studies, respectively (Douillard et al, 2000; Saltz et al,
2000). The incidence of grade 3/4 diarrhoea in these two phase III
trials was 23 and 14%, respectively. In the weekly irinotecan plus
UFT with LV regimen, the most frequently reported grade 3/4
toxicities were neutropenia (11% of patients) and delayed
diarrhoea (28%) (Mendez et al, 2005).
UFT with LV treatment is a convenient, well-tolerated and
effective alternative to i.v. 5-FU/LV. A crossover study (n¼36)
evaluating patient preference for UFT with LV or i.v. 5-FU/LV
chemotherapy in mCRC showed that 84% of patients preferred
oral treatment over i.v. treatment (Borner et al, 2002). UFT may be
administered without visits to the hospital, resulting in reduced
treatment costs (Murad et al, 1997) and increased convenience for
the patient. The oral schedule also allows patients to temporarily
withhold a dose of the drug if adverse events emerge, for example
grade 2 diarrhoea, thereby preventing the toxicity from becoming
severe. Patients can then restart the medication after 1–2 days,
when the diarrhoea resolves (Hoff and Pazdur, 1998). Simply
eliminating several doses at the onset of early-stage diarrhoea can
prevent its progression to a serious or even life-threatening
toxicity that might otherwise require hospitalisation.
In conclusion, this phase II study has added to the clinical
evidence that UFT with LV is a good combination partner for
irinotecan in the treatment of patients with non-resectable mCRC.
The results from this study suggest that administration of
irinotecan every 3 weeks plus daily UFT with LV is a feasible,
well-tolerated and convenient treatment option for patients with
this condition.
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